EDGEWISE THERAPEUTICS INC's ticker is EWTX and the CUSIP is 28036F105. A total of 130 filers reported holding EDGEWISE THERAPEUTICS INC in Q1 2024. The put-call ratio across all filers is 1.01 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,437 | 0.0% | 80,000 | 0.0% | 0.00% | 0.0% |
Q1 2024 | $1,437 | +56.2% | 80,000 | 0.0% | 0.00% | +50.0% |
Q4 2023 | $920 | +95.3% | 80,000 | 0.0% | 0.00% | +100.0% |
Q3 2023 | $471 | -21.8% | 80,000 | 0.0% | 0.00% | 0.0% |
Q2 2023 | $602 | +201.0% | 80,000 | +166.7% | 0.00% | 0.0% |
Q1 2023 | $200 | -24.5% | 30,000 | 0.0% | 0.00% | 0.0% |
Q4 2022 | $265 | -99.9% | 30,000 | 0.0% | 0.00% | 0.0% |
Q3 2022 | $291,000 | +90.2% | 30,000 | +51.5% | 0.00% | – |
Q2 2022 | $153,000 | -16.4% | 19,800 | 0.0% | 0.00% | – |
Q1 2022 | $183,000 | -32.0% | 19,800 | +10.0% | 0.00% | -100.0% |
Q4 2021 | $269,000 | – | 18,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
New Leaf Venture Partners, L.L.C. | 1,553,661 | $27,981,435 | 34.02% |
Novo Holdings A/S | 6,344,430 | $114,263,184 | 6.63% |
Orbimed Advisors | 15,021,721 | $270,541,195 | 5.34% |
TCG Crossover Management, LLC | 2,272,728 | $40,931,831 | 4.27% |
Frazier Life Sciences Management, L.P. | 3,731,067 | $67,196,517 | 3.14% |
Cormorant Asset Management, LP | 3,006,534 | $54,147,677 | 3.13% |
Opaleye Management Inc. | 580,000 | $10,445,800 | 2.39% |
RA Capital Management | 8,909,091 | $160,452,729 | 2.12% |
VR Adviser, LLC | 1,818,182 | $32,745,458 | 2.08% |
MPM BioImpact LLC | 740,661 | $13,339,305 | 2.07% |